Doctors at the American College of Cardiology's annual meeting are reporting an exciting win for gene testing and personalized medicine: Checking patients' DNA before starting them on a popular blood thinner helps get the tricky dose right and keep them out of the hospital. Patients given gene tests to set their initial warfarin dose had about a 30 percent lower risk of being hospitalized than similar patients whose doses were set by trial and error. "This may help make this a safer drug to utilize," said James McClurken, chief of the cardiology conference and a heart surgeon at Temple, in a widely distributed Associated Press story.